CGN-1 Neurotropic Capsid

About Capsigen

Capsigen is a private, pre-clinical stage biotech focused on solving the critical delivery challenges in gene therapy through advanced capsid engineering. Its core technology, the Transcription-Dependent Directed Evolution (TRADE™) platform, enables the rapid discovery and optimization of novel AAV capsids tailored to specific disease criteria, with a claimed timeline of about one year to a fit-for-purpose candidate. The company has established a strategic research collaboration with Biogen, signaling early validation of its platform for central nervous system and neuromuscular disorders, and operates as a platform technology company seeking partnerships to advance novel gene therapies.

Therapeutic Areas